Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20667984 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10TLR8TLR7 | |
| SCHEMBL5426412 | 0.91 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10LMNAMAPT | |
| SCHEMBL31044731 | 0.87 | TLR8 (0.43) | TLR8TLR7GBA1 | |
| SCHEMBL31045039 | 0.84 | APP (0.51) | TLR8TLR7GBA1CYP1A2CYP2D6 | |
| SCHEMBL31044874 | 0.84 | — | — | |
| SCHEMBL29992067 | 0.84 | CYP1A2 (0.41) | TLR8TLR7GBA1SMN1; SMN2L3MBTL1 | |
| SCHEMBL20667986 | 0.83 | TLR8 (0.41) | TLR8TLR7GBA1CYP1A2CYP2D6 | |
| SCHEMBL5444802 | 0.83 | ICAM1 (0.48) | ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL5435521 | 0.83 | MTNR1A (0.46) | — | |
| SCHEMBL31044779 | 0.82 | CYP1A2 (0.40) | TLR8TLR7GBA1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| CN-101061122-A | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | GRM2, GRIA2, GRM1 | ALDH1A1 3149/4885KDM4E 1994/4885HSD17B10 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.